Literature DB >> 3357420

Quantification of the glycolytic origin of plasma glycerol: implications for the use of the rate of appearance of plasma glycerol as an index of lipolysis in vivo.

N Nurjhan1, F Kennedy, A Consoli, C Martin, J Miles, J Gerich.   

Abstract

To assess whether plasma glycerol could be directly derived from plasma glucose, nine postabsorptive dogs were infused with [U-14C] glucose and [2-3H] glycerol to measure the rates of appearance of plasma glucose and glycerol and the conversion of plasma glucose to glycerol before (basal) and after two hours of infusion of glucose (45 mumol/kg/min). Basally (plasma glucose 4.9 +/- 0.2 mmol/L; plasma insulin 5.9 +/- 0.2 microU/mL), rates of appearance of plasma glucose and glycerol were 20 +/- 2 and 5.9 +/- 1.3 mumol/kg/min, respectively, and 1.6 +/- 0.6% of plasma glycerol was derived from plasma glucose. After glucose infusion (plasma glucose 9.1 +/- 0.7 mmol/L; plasma insulin 21.1 +/- 1.9 microU/mL), the rate of appearance of plasma glycerol decreased 80% to 1.1 +/- 0.3 mumol/kg/min and the percent of plasma glycerol from glucose increased significantly to 6.9 +/- 2.9. However, the absolute rate of conversion of glucose to glycerol did not change (0.09 +/- 0.03 v 0.07 +/- 0.03 mumol/kg/min). We conclude that even under conditions of stimulated glycolysis and inhibited lipolysis, only a small amount of plasma glycerol is derived from plasma glucose. Thus, rates of appearance of plasma glycerol can be used as a measure of rates of overall lipolysis in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3357420     DOI: 10.1016/0026-0495(88)90140-0

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  Metabolic signatures of exercise in human plasma.

Authors:  Gregory D Lewis; Laurie Farrell; Malissa J Wood; Maryann Martinovic; Zoltan Arany; Glenn C Rowe; Amanda Souza; Susan Cheng; Elizabeth L McCabe; Elaine Yang; Xu Shi; Rahul Deo; Frederick P Roth; Aarti Asnani; Eugene P Rhee; David M Systrom; Marc J Semigran; Ramachandran S Vasan; Steven A Carr; Thomas J Wang; Marc S Sabatine; Clary B Clish; Robert E Gerszten
Journal:  Sci Transl Med       Date:  2010-05-26       Impact factor: 17.956

Review 2.  Is muscle the major site of insulin resistance in type 2 (non-insulin-dependent) diabetes mellitus?

Authors:  J E Gerich
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

3.  Increased lipolysis and its consequences on gluconeogenesis in non-insulin-dependent diabetes mellitus.

Authors:  N Nurjhan; A Consoli; J Gerich
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

4.  Methods for quantifying adipose tissue insulin resistance in overweight/obese humans.

Authors:  K W Ter Horst; K A van Galen; P W Gilijamse; A V Hartstra; P F de Groot; F M van der Valk; M T Ackermans; M Nieuwdorp; J A Romijn; M J Serlie
Journal:  Int J Obes (Lond)       Date:  2017-05-03       Impact factor: 5.095

5.  Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine.

Authors:  M Stumvoll; U Chintalapudi; G Perriello; S Welle; O Gutierrez; J Gerich
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

Review 6.  Tracking the carbons supplying gluconeogenesis.

Authors:  Ankit M Shah; Fredric E Wondisford
Journal:  J Biol Chem       Date:  2020-08-13       Impact factor: 5.157

7.  Glycerol Production from Glucose and Fructose by 3T3-L1 Cells: A Mechanism of Adipocyte Defense from Excess Substrate.

Authors:  María del Mar Romero; David Sabater; José Antonio Fernández-López; Xavier Remesar; Marià Alemany
Journal:  PLoS One       Date:  2015-10-01       Impact factor: 3.240

8.  Glycerol is synthesized and secreted by adipocytes to dispose of excess glucose, via glycerogenesis and increased acyl-glycerol turnover.

Authors:  Floriana Rotondo; Ana Cecilia Ho-Palma; Xavier Remesar; José Antonio Fernández-López; María Del Mar Romero; Marià Alemany
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.